All three of the drug chains have implemented major private-label upgrades. Among the efforts: • Walgreens is on track to double its private-label sales to $8 billion within the next five to seven years. To do so, the drug chain is in the midst of a major private-label consolidation that will pare the 75-brand program down to just a few core lines. Key to the effort was the recent launch of Nice, a 300-item line of grocery and household products. At the same time, the ...
SIGN IN TO ACCESS THIS ARTICLE
Registering for Premium Content on Supermarket News will give you INSTANT access to invaluable articles and media content that industry professionals rely on. You will have access to our special reports, feature articles, and industry analysis. It’s FREE, easy and quick.